Business
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1MNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio’s revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over y
About this update from Precipio, Inc.
[{"type":"image","alt":"Precipio, Inc.","displaySize":"","headline":null,"caption":"Precipio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/ab6e80c50d815f9c4c3c5c7425f16fed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zOITnXM5v3wqbUHIrLobqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab6e80c50d815f9c4c3c5c7425f16fed","width":300,"height":59}},"lazy":false},{"type":"text","content":"In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M","length":99,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025.","length":216,"tagName":"p","attribs":{}},{"type":"text","content":"Below are some of the key financial performance metrics for the Company.","length":72,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue Growth – Precipio’s revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. ","length":195,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please see a more detailed explanation Adjusted EBITDA at the bottom of this press release. ","length":301,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Positive operating cash flow - Precipio will report $368K of positive operating cash flow during Q4-2025, and a total of $688K for 2025. This is compared to $439K of cash generated from operations in 2024. These amounts include certain unusual items related to Change Healthcare transactions and the COVID-related Employee Retention Credit. Excluding the unusual items, the Company’s adjusted operating cash flow was $617K for Q4-2025 and a total of $727K for 2025.","length":465,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":961},{"type":"text","content"...